About
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovativ
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 5 investors are based in Valby, Hovedstaden, Denmark.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech
- Location
- Valby, Denmark
Contact Information
Find more investors like Lundbeck
Search Investors